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It is now admitted that the immune system plays a major role in tumor control. Besides
the existence of tumor-specific T cells and B cells, many studies have demonstrated that
high numbers of tumor-infiltrating lymphocytes are associated with good clinical outcome.
In addition, not only the density but also the organization of tumor-infiltrating immune cells
has been shown to determine patient survival. Indeed, more and more studies describe
the development within the tumor microenvironment of tertiary lymphoid structures (TLS),
whose presence has a positive impact on tumor prognosis. TLS are transient ectopic lym-
phoid aggregates displaying the same organization and functionality as canonical secondary
lymphoid organs, withT-cell-rich and B-cell-rich areas that are sites for the differentiation of
effector and memoryT cells and B cells. However, factors favoring the emergence of such
structures within tumors still need to be fully characterized. In this review, we survey the
state of the art of what is known about the general organization, induction, and functionality
of TLS during chronic inflammation, and more especially in cancer, with a particular focus
on the B-cell compartment. We detail the role played byTLS B cells in anti-tumor immunity,
both as antigen-presenting cells and tumor antigen-specific antibody-secreting cells, and
raise the question of the capacity of chemotherapeutic and immunotherapeutic agents to
induce the development of TLS within tumors. Finally, we explore how to take advantage
of our knowledge on TLS B cells to develop new therapeutic tools.
Keywords: tertiary lymphoid structure, cancer, B cell, antibody, dendritic cell, anti-tumor immunity, biomarker,
immunotherapy
INTRODUCTION
Tumors represent a complex microenvironment that not only
includes tumor cells but also stromal cells, blood vessels, and
different immune cell populations, reflecting the capacity of the
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immune system to sense tumor cells (1). The major role played
by the immune system in tumor surveillance and control has been
extensively documented. Since the discovery of T cells, B cells, and
antibodies specific for tumor antigens (2–6), several clinical stud-
ies have clearly demonstrated that a high density of T-cell or B-cell
subsets within the tumor microenvironment is associated with
increased patient survival (1, 7, 8), such as in colorectal cancer (9),
primary cutaneous melanoma (10), breast cancer (11–14), non-
small cell lung cancer (NSCLC) (15, 16), head and neck cancer
(17), and ovarian cancer (18–20).
Regarding the development of adaptive anti-tumor immune
responses (but it is also true for any other kind of disorders), the
dogma was that infiltrating anti-tumor immune cells are edu-
cated to recognize tumor antigens and proliferate at distance
of the tumor site, in conventional secondary lymphoid organs
(SLOs), and are then recruited to the tumor microenvironment
to exert their anti-tumor activity. SLOs are highly specialized
tissues that arise at predetermined locations during embryoge-
nesis and persist all over the life. They include lymph nodes
(LNs), spleen and mucosal-associated lymphoid tissues (MALTs),
namely Peyer’s patches, tonsils, and nasal-associated lymphoid tis-
sues (NALTs) or bronchus-associated lymphoid tissues (BALTs).
However, it is now established that immune responses can also
take place at distance of SLOs, in tertiary lymphoid structures
(TLS), also called tertiary lymphoid organs (TLOs) or, in the case
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of the lung, (T)i-BALTs, for (tumor-) induced BALTs (21–23). As
opposed to SLOs, TLS are defined as transient ectopic lymphoid
organizations that can develop after birth in non-lymphoid tis-
sues, in situations of chronic inflammation. This phenomenon
is usually termed lymphoid “neogenesis” by opposition to lym-
phoid organogenesis, which refers to SLO development (24, 25).
TLS have already been observed in several infectious diseases, graft
rejection, autoimmune disorders [including rheumatoid arthritis
(RA) and multiple sclerosis], allergy, and cancer (25–27). They
have also been described in different lung inflammatory diseases,
such as fibrosis, pneumonia, hypersensitivity pneumonitis, diffuse
pan-bronchiolitis, and tobacco-induced inflammation (28), and
in the adventitia of human atherosclerotic arteries (29–31). It has
been proposed that the presence of TLS can be observed in every
situation when the inflammatory response initiated is unable to
eradicate the associated antigen (32). This inability might be the
result of an efficient escape of a pathogen antigen to immune
surveillance, and/or of a permanent replenishment of a self or
tumor antigen by the tissue. The difficulty in eradicating anti-
gens would lead to a chronic inflammation, characterized by a
sustained infiltration of immune cells, and to the development of
TLS as sites for the generation of a local more efficient immune
response. Because these structures turn off after the resolution of
the inflammation, they have been proposed as a genuine inflam-
mation marker (27). In autoimmune diseases and transplantation,
the presence of TLS is respectively associated with disease exac-
erbation, poor outcome (33), chronic rejection, and anti-graft
responses (34–37). On the opposite, T- and B-cell responses ini-
tiated within TLS during infections are associated with pathogen
clearance, increased survival, and reduced morbidity (21). Finally,
an increasing number of studies demonstrated over the past
decades that the presence of TLS in the tumor microenvironment
is associated with anti-tumor immune responses and prolonged
patient survival (22, 27, 38–44). Yet, the events that influence
immune cell infiltration and TLS formation are still incompletely
understood.
In this review, we discuss the factors favoring the recruitment
of immune cells and their organization in TLS by comparison
with what is known about conventional SLOs. We detail the role
played by TLS B cells in anti-tumor immunity, both as tumor
antigen-specific antibody-secreting cells and antigen-presenting
cells (APCs). Finally, we raise the question of the capacity of
chemotherapeutic agents and/or new immunotherapeutic drugs
to induce the development of TLS within tumors, and how to take
advantage of what we know now from these structures to develop
new therapeutic tools.
TLS ORGANIZATION AND FORMATION: HOW FAR A TLS IS
LIKE A LN?
TLS DISPLAY THE SAME ORGANIZATION AS CONVENTIONAL SLOs
LN, a prototypical SLO
Lymph nodes are encapsulated structures mainly composed of
T cells and B cells, dendritic cells (DCs), a network of fibrob-
lastic reticular cells (FRCs) and fibers (45), and two special-
ized lymphatic and vascular systems: lymphatic vessels and high
endothelial venules (HEVs), the latter specifically allowing the
recruitment of naive T and B lymphocytes, but also plasmacytoid
DCs (pDCs) and the precursors of conventional (CD11chi) DCs
(pre-cDCs) into the LN [reviewed in Ref. (46)].
Within LNs, B, and T cells are segregated into distinct func-
tional areas: a B-cell area mainly composed of densely packed
B cells and follicular DCs (FDCs) forming follicles, and a T-
cell area mainly composed of less dense accumulation of T cells
and DCs (25). While DCs prime T cells through the presenta-
tion of antigen-derived peptides within major histocompatibility
complex (MHC) class I and II molecules, FDCs shape the B-
cell response by presenting unprocessed antigens in the form of
antigen-antibody complexes that they trap through their com-
plement or fragment constant receptors (FcRs). After antigen
encounter, activated B cells organize into a germinal center (GC),
which is a site of active B-cell proliferation, class switch recombi-
nation (CSR), and somatic hyper-mutation (SHM), allowing the
generation of B-cell clones highly specific for the antigen. A par-
ticular subset of T helper (Th) cells, namely T follicular helper
(Tfh) cells, plays also a major role in GC responses, by delivering
key signals for GC B-cell survival and differentiation [reviewed in
Ref. (47)].
TLS, similarities and differences with LNs
Tertiary lymphoid structures were shown to display an overall
organization very similar to that observed in SLOs. In NSCLC
for example, we showed that TLS were composed of a T-cell-rich
area, characterized by T cells forming clusters with mature DCs
expressing the maturation marker DC-Lamp, and CD20+ B cells,
organized in B-cell follicle (Figure 1) (22, 39). Like in conven-
tional LNs, B-cell follicles were composed of a mantle of IgD+
naive B cells, surrounding a GC identified by highly proliferat-
ing Ki67+ B cells and a network of CD21+ FDCs. Expression of
activation-induced cytidine deaminase (AID) and of the transcrip-
tion repressor Bcl6 by GC B cells, associated with CSR and SHM
activities, was reported in several studies (32, 39, 40, 48). Finally,
the presence of CD68+ tingible-body macrophages (specialized in
the clearance of apoptotic B cells) and CD3+ CD4+ CXCL13+ Tfh
cells could also be detected within TLS B-cell follicles (39, 43), as
well as that of differentiated plasma cells (PCs) (39, 49, 50).
Like in SLOs, the presence of TLS is frequently associated with
that of HEVs. HEVs can be easily distinguished from other types
of blood vessels, thanks to a cuboidal endothelial cell lining and
a set of molecules expressed by endothelial cells: peripheral node
addressins (PNAd), which interact with L-selectin (CD62L) on
lymphocytes and allow lymphocyte tethering to HEV endothe-
lial cells and rolling along the HEV lumen; chemokines, including
CCL19, CCL21, CXCL10, CXCL12, and CXCL13, known to deter-
mine the trafficking of lymphocytes but also their segregation into
distinct areas within the LN (detailed below); and integrins and
immunoglobulin superfamily adhesion molecules, which support
the binding and migration of lymphocytes across HEVs (51, 52).
Because HEVs are crucial for the recruitment of lymphocytes into
LNs, they are also supposed to play a major role in tumor infiltra-
tion by immune cells and TLS formation (40, 53–56). Indeed, we
observed in lung cancer that most TLS T cells and B cells (except
GC B cells) expressed the PNAd ligand CD62L (53). Similarly, Mar-
tinet et al. demonstrated that the presence of HEVs in melanoma
tumors was associated with high levels of lymphocyte infiltration
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FIGURE 1 | Role ofTLS B cells in the initiation of a protective
anti-tumor immune response. As in canonical SLOs, TLS may represent
a critical site where specific T and B cells can undergo terminal
differentiation into effector cells in the T- and B-cell-rich areas, respectively.
In the latter case, germinal center B cells establish intimate interactions
with FDCs and Tfh in the course of differentiation into memory B cells and
PCs. This step is under the activation of CSR and SHM machineries.
Apoptotic B cells will be phagocytosed by TBM whereas fully
differentiated B cells will leave TLS B-cell follicle to the tumor stroma. After
binding to their cognate tumor antigens, antibodies will elicit ADCC, CDC,
and/or complement activation. Abbreviations: ADCC, antibody-dependent
cellular cytotoxicity; CDC, complement-dependent cytotoxicity; CSR, class
switch recombination; FDC, follicular dendritic cell; SHM, somatic
hyper-mutation; TBM, tingible-body macrophage; TCM, central-memory T
cell; TEM, effector-memory T cell; Tfh, follicular helper T cell; TLS, tertiary
lymphoid structure.
(54). They notably showed that lymphocytes specifically infiltrated
HEV-rich areas of melanoma tumors, and that the density of
HEVs was strongly correlated with DC-Lamp+ mature DC den-
sity and CD3+, CD8+, and CD20+ tumor-infiltrating lymphocyte
densities (55).
Interestingly, a major difference between SLOs and TLS is
the absence of natural killer (NK) cells within TLS, as demon-
strated in NSCLC using the NKp46 marker (57). To date, the
presence of NK cells has never been reported in TLS regardless
of the pathology concerned (cancer, autoimmunity, transplanta-
tion, or infectious diseases). In LNs, NK cells colocalize with DCs
in the T-cell area (58), and form clusters with DCs and T cells
getting primed shortly after infection, during the early phases
of the adaptive immune response (59–61). On one hand, acti-
vated DCs can enhance NK cell proliferation, IFNγ secretion, and
cytotoxic functions through the production of cytokines such as
IL-15, IL-12, IL-18, and IFNα/β. On the other end, NK cells can
either promote DC maturation through the production of IFNγ
and TNFα, or kill immature DCs [reviewed in Ref. (62)]. Sim-
ilarly, NK cells are thought to provide an early source of IFNγ
that is needed to polarize the T-cell response (63), while newly
primed Ag-specific CD4+ T cells can directly activate NK cells
through the secretion of IL-2 (60, 64). These interactions are
supposed to play a crucial role in shaping both innate and adap-
tive immune responses in LNs (65). The fact that intra-tumoral
NK cells are not observed within cancer-associated TLS (57, 66)
indicates that tumor-infiltrating NK cells may not influence T-
cell response, and are not the cellular source of IFNγ detected
within TLS.
TLS NEOGENESIS, WHAT CANWE LEARN FROM LN ORGANOGENESIS?
LN development
The development of LNs during embryogenesis depends on
interactions between a unique subset of CD45+CD4+CD3-
hematopoietic cells, named lymphoid tissue-inducer (LTi) cells
and resident stromal cells, qualified as lymphoid tissue-organizer
(LTo) cells (67). In mice, van de Pavert et al. showed that the ini-
tial interaction between these two cell subsets was triggered by
CXCL13 produced by stromal LTo cells at sites of lymphoid tissue
formation, inducible upon retinoic acid and neuronal stimulation,
and able to attract CXCR5-expressing LTi cells (68). The engage-
ment of lymphotoxin (LT), a member of the TNF family expressed
as an LTα1β2 heterotrimer on LTi cells, with lymphotoxin β recep-
tor (LTβR) on stromal cells, then leads to the activation of two
different pathways of the NF-κB transcription factor, resulting in
the expression of high levels of the intercellular and vascular cell
adhesion molecules ICAM-1 and VCAM-1, production of lym-
phoid chemokines (CCL19, CCL21, and CXCL13) and cytokines,
and the development of both HEVs and lymphatic vessels (51, 69–
72). The local expression of lymphoid chemokines by stromal LTo
cells allows the subsequent attraction and trafficking of B, T, and
DCs to the LN (67, 68). These three homeostatic chemokines not
only govern the recruitment but also the positioning of immune
cells within the LN. While CCL19 and CCL21 are expressed by the
T-cell-zone stromal cells, and interact both with CCR7 to orches-
trate the homing of naive and central-memory T cells and DCs to
the T-cell compartment, CXCL13 is expressed by the B-cell-zone
stromal cells, and allows the recruitment of CXCR5+ B cells and
Tfh to the follicular compartment (73). Of note, CXCL13 was also
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shown to promote LTα1β2 expression on the surface of LTi cells,
which amplifies the LTβR signaling in stromal LTo cells, resulting
in a positive and stable feedback loop (67). Another feedback loop
involving CXCL13 and LTα1β2 was also observed between FDCs
and B cells, which are themselves strong producers of LTα and LTβ
(74). LTα1β2 expression by B cells plays notably a major role in the
establishment of the FDC network and in B-cell follicle organiza-
tion. However, it has been demonstrated that membrane-bound
LTα1β2 on B cells was a key regulator of CXCL13 production
by FDCs, which in turn induces an upregulation of LTα1β2 on
B cells (75).
HEV endothelial cells also express LTβR, and several studies
have demonstrated that continuous engagement of LTβR on HEVs
by LTα1β2+ cells is critical for the induction and maintenance of
HEV gene expression and HEV endothelial cell morphology (70,
76). In mice, B cells (71, 77) and CD11c+ DCs (78) were both
demonstrated as major sources of LTα1β2 for HEV regulation in
lymphoid tissues. CD11c+ DCs in particular were shown to play an
essential role in lymphocyte homing to the LNs, as a direct or indi-
rect source of pro-angiogenic factors favoring the development of
HEVs (79, 80). Webster et al. notably showed in immunized mice
that CD11c+ DCs were able to induce increased vascular endothe-
lial growth factor (VEGF) levels in LNs, favoring endothelial cell
proliferation including HEV endothelial cell growth, associated
with increased immune cell entry (81). In a further study, the
same group showed that CD11c+ DC-induced vascular growth in
this model is at least in part mediated by the production of IL-
1β by CD11c+ DCs that can directly stimulate FRC proliferation
and VEGF production (82). Similarly, activated B cells are able
to secrete the pro-lymphangiogenic factor VEGF-A, and to drive
lymphangiogenesis in inflamed LNs (83).
TLS neogenesis
The physiological events that lead to TLS formation are still
unclear, in particular in cancer. Numerous studies in inflamma-
tory disorders tried to determine if the same cell types and/or
molecules involved in lymphoid organogenesis, could similarly be
implicated in TLS neogenesis. If the presence of the bona fide LTi
cells does not seem to be required for TLS induction in CCL21-
transgenic LTi-deficient mice (84), many studies showed that key
molecules, such as LT, CCL21, or CXCL13 chemokines, play also
a major role in lymphoid neogenesis. Grabner et al. for example
demonstrated in a mouse model of atherosclerosis that the activa-
tion through LTβR of medial smooth muscle cells (SMCs) in the
abdominal aorta led to the expression of CCL19, CCL21, CXCL13,
and CXCL16 chemokines, which in turn triggered the recruitment
of lymphocytes to the adventitia and the development of TLS (85).
In this study, authors suggest that the cellular source of LT would be
CD11c+CD68+Ly6Clo monocytes that accumulate in atheroscle-
rotic plaques. Interestingly, Thaunat et al. showed in a rat model
of chronic allograft rejection based on aorta transplantation that
macrophages, together with CD4+ and CD8+ T cells, are one of
the first immune cell subsets infiltrating the adventitia few days
after engraftment, simultaneously with the acquisition by some
endothelial cells of a HEV-like phenotype (37). The same group
demonstrated that macrophages, in particular M1-polarized pro-
inflammatory macrophages that express high levels of LTα and
TNFα, can act as LTi cells in diseased arteries and confer a LTo phe-
notype to vascular SMCs, but that this mechanism is TNF receptor
1/2 (TNFR1/2) signaling-dependent and LTβR-independent (86).
They explained the discrepancies observed between their study and
others claiming that LTβR is crucial for the formation of TLS by
the major role played by LTβR in inducing CXCL13 production,
cytokine not indispensable to induce TLS in their model. Simi-
larly, Moyron-Quiroz et al. were able to observe the formation of
i-BALTs in mice upon influenza infection even in the absence of
LTα, but not as well organized as the ones generated in wild-type
mice, with B-cell areas devoid of FDCs, few intermixed T cells, and
no expression of PNAd (21). Finally, in human NSCLC, we were
able to detect the expression of a set of chemoattractants associ-
ated with T lymphocytes in TLS, including the previously cited
chemokines CCL19, CCL21, and CXCL13 (53).
In accordance with the aforementioned role of DCs in lym-
phocyte homing to LNs, it was suggested that DCs could promote
lymphocyte tumor infiltration through the regulation of tumor
HEVs (87). Indeed, Martinet et al. showed that LTβwas specifically
overexpressed in breast cancers characterized by a high density of
HEVs, and that the major producers of LTβ in the tumor microen-
vironment were DCs. They notably showed that LTβ expression
correlated with that of HEV-associated chemokines, and that DC-
Lamp+ DC density correlated with HEV density, lymphocyte
infiltration, and favorable clinical outcome (88). In mice, CD11c+
DCs were shown to play a major role in the maintenance of i-
BALTs. Halle et al. for example demonstrated a massive infiltration
of CD11c+ DCs followed by i-BALT neogenesis in the lung of
modified vaccinia virus Ankara (MVA)-infected mice, and that the
depletion of these cells after i-BALT formation resulted in strong i-
BALT size reduction (89). Similarly, GeurtsvanKessel et al. showed
in a mouse model of influenza virus infection that CD11chi DCs
are essential for the maintenance of virus i-BALTs after virus clear-
ance, as DC depletion resulted in reduced i-BALT numbers, associ-
ated with reduced B-cell density within the remaining clusters, and
altered humoral immunity (49). This effect was associated with
LTβ expression by DCs, as blocking LTβR signaling had the same
effect as DC depletion. Inhibition of LTβR signaling was associated
with reduced secretion of CXCL13, suggesting that DCs maintain
i-BALTs by providing a continuous source of LTβ that is necessary
for high CXCL13 production and retention of B cells. Interestingly,
authors showed that repeated injections of DCs also led to the
development of i-BALTs into naïve mice suggesting that DCs may
have a direct action in lymphoid neogenesis. Finally, Marinkovic
et al. showed in a CCL21-transgenic-LTi-deficient mouse model
that the formation of thyroid-associated TLS started by the clus-
tering of host tissue DCs with newly entered mature CD3+ CD4+
T cells, followed by the formation of PNAd+ HEVs (84).
It has been suggested that Th17 cells could also play a major
role in TLS induction. Th17 cells and associated cytokines are ele-
vated in a number of autoimmune and inflammatory diseases,
in which their function is well documented [reviewed in Ref.
(90)]. Their role in cancer however is more uncertain, due to their
strong plasticity [reviewed in Ref. (91)]. The putative role of Th17
cells in TLS development notably comes from the observation
that Th17 cells share many developmental and effector markers
with LTi cells. It includes the nuclear hormone receptor retinoic
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acid-related orphan receptorγt (RORγt), which promotes the pro-
duction of IL-17 and IL-22 by Th17 cells, LTi cells, and other
RORγt+ innate lymphoid cells (ILCs); the chemokine receptor
CCR6, which favors the recruitment of Th17 cells to the site of
inflammation in response to its ligand CCL20; and the ligand-
dependent transcription factor, aryl hydrocarbon receptor (AHR).
Above all, both cell subsets express LTα1β2 on the cell membrane
[reviewed in Ref. (92)]. The role of Th17 cells in TLS induction was
particularly studied in mouse models of lung infection or autoim-
munity. Rangel-Moreno et al. for example demonstrated in mice
sensitized with LPS that i-BALT formation was dependent on IL-
17 production by T cells, including Th17 cells and γδ T cells, while
LTi cells were not necessary (93). Opposite results were obtained
by Fleige et al., who showed in MVA-infected mice that i-BALT for-
mation was independent of IL-17 (94). The same authors further
deciphered this duality in another study, in which they suggested
that the role played by IL-17 in i-BALT development depends on
the type of inflammation-inducing pathogen (95). Actually, they
showed that while mice infected with MVA developed in their
lungs highly organized i-BALTs, with densely packed B-cell follicles
characterized by CXCL12-producing stromal cells and a network
of CXCL13+ FDCs, mice infected with P. aeruginosa developed
i-BALTs with B-cell follicles that contained CXCL12-expressing
stromal cells but lacked FDCs. Authors demonstrated that in the
case of P. aeruginosa infection, IL-17 drives the differentiation of
lung stroma toward CXCL12-expressing cells, which allows B-cell
recruitment and follicle formation even in the absence of FDCs.
Again, the major source of IL-17 was identified here as being γδ
T cells within i-BALTs. Still in favor of IL-17 involvement in TLS
induction, Peters et al. showed in a mouse model of multiple scle-
rosis [experimental autoimmune encephalomyelitis (EAE)] that
the transfer of differentiated myelin oligodendrocyte glycoprotein
(MOG)-specific Th17 cells was more capable of inducing ectopic
lymphoid structures than other Th subtypes (96). Ectopic lym-
phoid structure development was notably associated here with the
acquired expression by transferred Th17 cells of Tfh cell-associated
molecules, such as CXCR5, ICOS, and Bcl6, and dependent on
the expression of IL-17 by Th17 cells. Finally, in humans, Deteix
et al. suggested that Th17 cells, and IL-17 and IL-21 secretion
by these cells, promote lymphoid neogenesis within human renal
grafts, and are associated with fast chronic rejection (97). They
notably showed that while rejected renal grafts from slow progres-
sor patients were characterized by the presence of IL-10-secreting
regulatory T cells (Tregs), which positively correlated with graft
survival, rejected renal grafts from fast progressor patients were
characterized by the presence of IL-17- and IL-21-secreting Th17
cells, which negatively correlated with graft survival. In addi-
tion, the presence of Th17 cells correlated with the presence of
AID+ GC B cells suggesting that Th17 cells promote intragraft
neogenesis through the production of IL-21, which in turn stim-
ulates intragraft B cells, with deleterious consequences on kidney
transplant.
In accordance with the aforementioned study, it has been
proposed that Tregs could impair TLS formation. Kocks et al.
for example observed that CCR7-deficient mice spontaneously
develop very organized BALTs under steady-state conditions (98).
Because BALT occurrence was reverted by the adoptive transfer of
CCR7-expressing wild-type Tregs, authors suggested that Tregs
may play a role in controlling BALT formation. It is empha-
sized in this study that BALTs may not be bona fide TLS, as they
arise in absence of any inflammatory signals. In parallel, Hind-
ley et al. showed in carcinogen-induced tumor-bearing mice that
Treg depletion allowed the development of HEVs within tumors,
associated with higher expression of LTα, LTβ, CCL19, CCL21,
and CXCL13, higher CD8+ T-cell infiltration, and lower tumor
growth (99). These observations are in accordance with the study
of Martinet et al., who showed a decreased FoxP3+/CD3+ T-cell
ratio in HEVhi human breast tumors (88).
Thus, if factors influencing TLS formation are still unclear, in
particular in cancer, three critical events definitively appear to pro-
mote TLS formation: inflammatory cytokine production (such as
LTα/β), lymphoid chemokine production, and HEV development
(25). By their capacity to produce LT and pro-angiogenic factors,
it appears that B cells and DCs may participate in the initiation
and/or maintenance of TLS.
DOUBLE FACE OF B CELLS IN TUMOR IMMUNITY
DELETERIOUS EFFECTS OF B CELLS IN ANTI-TUMOR IMMUNITY
For a long time, the deleterious or positive role of B cells in anti-
tumor immune response was a matter of debate. Many studies
reported a pro-tumoral role of B cells in cancer patients and
tumor mice models. For example, the detection of specific anti-
bodies in the serum or in the tumor of breast cancer patients
was associated with poor prognosis (100). In advanced colorectal
cancer, a reduction of the tumor size following B-cell depletion
could be observed in half of the patients treated with Rituximab,
a humanized monoclonal antibody directed against human CD20
(101). Several mechanisms have been proposed to explain this pro-
tumoral effect, using inactivated genes, xenograft experiments,
adoptive cell transfer, or systemic B-cell depletion in mice models.
The participation and/or the maintenance of a chronic inflamma-
tion by B cells leading to the growth of the tumor have notably been
suggested (102). Also, when bound to antigens into immune com-
plexes, antibodies can activate the complement system, which can
trigger inflammation in B-cell deficient (µMT) or B-cell depleted
mice. Indeed, the secretion of mediators like anaphylatoxins (i.e.,
C3 and C5a components) can induce the recruitment of inflam-
matory cells which in turn may provide a rich pro-angiogenic
and pro-tumoral environment (103). Depending on the con-
text, immune complexes can also promote tumor growth via the
degradation of the extracellular matrix and the promotion of
angiogenesis in a granulocyte- and macrophage-dependent man-
ner (104). B cells were shown to directly inhibit cytotoxic T-cell
responses in colorectal, melanoma, and thymoma tumor models
in µMT mice (105). In addition, B-cell-derived factors, like TGF-
β and IL-10, can favor the differentiation and the recruitment
of Tregs, further amplifying the immunosuppressive environment
(106, 107). Lastly, it has been proposed that LT produced by
B cells could favor tumor metastasis in an NF-κB-independent
manner (74). This phenomenon was notably demonstrated in
a mouse model of castration-resistant prostate cancer, in which
tumor cell death induced by castration elicited an inflammatory
response, associated with inflammatory chemokine production
and recruitment of immune cells. In this model, newly recruited
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mature B2 cells induced the activation of prostate cancer cells via
LT-LTβR signaling, followed by IKK-α nuclear translocation and
STAT3 activation, ultimately enhancing androgen-independent
tumor growth and spreading. However, some of these studies,
like ones in µMT mice, have to be interpreted with caution, as
mice used in these experiments have also profound defects in
TCR repertoire usage and strong disruption of lymphoid tissue
architecture with diminished FDC, DC, and NK cell numbers.
BENEFICIAL EFFECTS OF B CELLS IN ANTI-TUMOR IMMUNITY
Recent studies readdressed this question using more relevant ani-
mal models. For instance, DiLillo et al. demonstrated a higher
growth of B16 melanoma and lung metastasis, associated with
decreased numbers of both CD4+ and CD8+ effector T cells, in
mice depleted in B cells using an anti-CD20 antibody as com-
pared with wild-type mice, demonstrating the key role of B cells
in the induction and maintenance of a protective anti-tumor cel-
lular immunity (108). In accordance with a beneficial role for
tumor-infiltrating B cells in some mouse models, numerous clini-
cal studies reported a positive correlation between the densities of
total B cells and the clinical outcome of cancer patients, such as
in NSCLC (15), primary cutaneous melanoma (10), breast cancer
(11, 12, 14), and ovarian cancer (18). Some studies included the
organization of tumor-infiltrating B cells as a supplementary crite-
ria to consider in addition to the cell density. Since then, markers of
TLS B-cell follicles (follicular B cells, Tfh cells, B-cell chemoattrac-
tant CXCL13) were all associated with prolonged cancer patient
survival (39, 43, 44). In chronic obstructive pulmonary disease
(COPD), TLS B cells have been shown to secrete both CXCL13
and LT (109). Thus, it is tempting to speculate that intra-tumoral B
cells may also play a beneficial role via the maintenance of cancer-
associated TLS which are associated with long-term survival. The
organization of B cells into TLS B-cell follicles may thus better
reflect the initiation of a local anti-tumor B-cell-mediated immu-
nity (18, 39, 110, 111). Actually, molecular analyses of TLS-derived
GC B cells from patients suffering from RA, primary Sjögren syn-
drome, or myasthenia gravis showed evidence of oligoclonal B-cell
proliferation and SHM of immunoglobulin variable genes (112–
115). In RA, the functionality of TLS was further demonstrated
by the presence of anti-citrullinated protein/peptide (ACPA) PCs
surrounding ectopic lymphoid structures in the synovial tissue of
patients (50). In metastatic melanoma patients, TLS B cells were
antigen experienced as demonstrated by the presence of clonal
amplification, somatic mutation, and isotype switching (40). We
similarly detected in NSCLC patients all stages of B-cell differen-
tiation within tumors, in accordance with the presence of AID+
GC B cells, differentiated memory B cells and plasmablasts within
TLS, and PCs within tumor stroma (Figure 1) (39). The demon-
stration of a direct correlation between the percentage of PCs and
the density of TLS follicular B cells in NSCLC tumors, together
with the capacity of tumor PCs to secrete antibodies specific for
tumor antigens (discussed below) were further evidence of TLS
B-cell functionality.
In parallel of their capacity to produce antigen-specific anti-
bodies, B cells can also act as powerful APCs for T-cell activation
and memory T-cell development (116, 117). It is known that
during antigen challenge, presentation of processed antigens by
B cells to CD4+ T cells in the outer follicle is necessary to the
full activation of B cells, and their differentiation into short-
lived plasmablasts or their proliferation and organization into
GC. Several ligand/receptor pairs are involved during the B-T-cell
interaction and also determine the extent of primary expansion
of CD4+ T cells, such as CD80-CD86/CD28, CD40/CD40L, and
OX40L/OX40, expressed on the surface of B cells and T cells,
respectively. Especially, interaction between CD40, that is con-
stitutively expressed by B cells, and its ligand CD40L which is
expressed by activated Th cells, is crucial for GC formation (47,
118). Besides of GC reaction, the contribution of B cells as APCs
was demonstrated in many disorders, including autoimmunity
and allograft rejection. In multiple sclerosis for instance, activated
B cells were shown to stimulate activation and proliferation of
myelin basic protein-specific autologous CD4+ T cells (119). Sim-
ilarly, in non-obese diabetic (NOD) mice, Serreze et al. showed that
B cells are necessary APCs for the initial priming of T-cell responses
against the candidate pancreatic β cell autoantigen glutamic acid
decarboxylase (GAD) (120). While NOD mice genetically deficient
in B lymphocytes were resistant to T-cell-mediated autoimmune
insulin-dependent diabetes mellitus, and failed to develop GAD-
specific T-cell responses, repopulation of mice with B lymphocytes
restored their ability to initiate anti-GAD T-cell immunity. This
observation was confirmed by Bouaziz et al. who showed that B-
cell depletion with an anti-CD20 antibody impaired CD4+ T-cell
activation and clonal expansion in response to protein antigens
and pathogen challenge, suggesting the requirement of both B
cells and DCs for optimal antigen-specific CD4+ T-cell prim-
ing (121). This result is in accordance with our observation in
NSCLC patients, in which high densities of both TLS mature DCs
and TLS B cells correlated with longer survival (39). However,
TLS mature DCHigh patients do not match perfectly with TLS B-
cellHigh patients. The combination of both biomarkers was the best
predictor for survival suggesting that both APCs may play a com-
plementary role in the initiation of protective immune responses
in NSCLC patients. The capacity of B cells to cross-present anti-
gens to CD8+ T cells is also well established (122–124). We notably
showed that 30-mer polypeptides derived from the cancer-testis
antigen NY-ESO-1 were efficiently cross-presented by B cells and
immunogenic, in that they induced the proliferation of nonamer-
specific CD8+ T cells in vitro (122). Finally, B cells would have
the capacity to reactivate T cells previously primed by DCs (125).
According to Nielsen et al., B cells may similarly serve as APCs
in cancer and thus promote anti-tumor T-cell responses (18).
Actually, authors observed that tumor-infiltrating CD20+ B cells
were often found in close proximity to CD8+ T cells, and that the
presence of both CD20+ and CD8+ lymphocytes was associated
with markedly prolonged survival of ovarian cancer patients com-
pared with that of CD8+ T-cell infiltrate alone. In addition, they
observed that tumor CD20+ B cells expressed several markers of
antigen presentation, such as MHC Class I and II molecules, as well
as the costimulatory molecules CD80 and CD86. In accordance
with that study, a high expression of CD40, CD80, and HLA-DR
was also reported by Yasuda et al. on tumor-infiltrating B cells in
primary lung cancer (126). Finally, some tumor-infiltrating B-cell
subsets may act as killer cells through the expression of granzyme
B and TRAIL, induce a Th1 polarization via the secretion of IFNγ
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and to a lesser extend IL12p40, as well as present processed anti-
gens to T cells through the expression of MHC class I, MHC class
II, and costimulatory molecules, as demonstrated in hepatocellular
carcinoma patients (127).
Lastly, the ligation of CD27 expressed by B cells to CD70
present on cytotoxic T lymphocytes (CTLs) was deemed critical
to sustain B-cell activation and immunoglobulin synthesis in an
antigen-independent manner, as well as to promote CTL survival
and proliferation (128). In contrast to ovarian and hepatocellu-
lar carcinomas (18, 127), memory B cells infiltrating lung tumors
are positive for CD27, which argues for an additional anti-tumor
immune function of intra-tumoral B cells (39).
As for T-cell infiltrate, it is necessary to take into account the
activation status and the cellular organization of intra-tumoral B
cells within the tumor microenvironment. The presence of TLS
may represent a privileged site where specific naïve B cells can
undergo their final differentiation into effector B cells, i.e., mem-
ory B cells and PCs, and thus may play a pivotal role in cellular-
and humoral-mediated anti-tumor immunity.
ANTIBODY RESPONSES TO TUMOR ANTIGENS IN THE
PERIPHERY AND IN SITU
It has been clearly established that tumor-infiltrating B cells, and in
particular cancer-associated TLS B cells, contribute to tumor prog-
nosis and are able to produce antibodies locally. Thus, the impor-
tant question to address is what these antibodies do, what their
specificity is, and whether produced antibodies may contribute
to the clinical outcome. In the 1980s, the knowledge that tumors
can elicit spontaneous humoral responses spurred the develop-
ment of autologous typing to identify novel molecular targets
(129, 130). One of the most prolific methods to discover tumor-
associated antigens was serological expression cloning (SEREX),
which originally used serum of a cancer patient to screen for targets
expressed in the autologous tumor after expression cloning (131).
This unbiased method led to the discovery of a series of novel
immunogenic targets, many of which were validated to be only
eliciting antibody responses in the context of tumors (132). NY-
ESO-1, discovered by SEREX, emerged as a model human tumor
antigen, with restricted expression in normal tissues to germline
cells, but widespread aberrant expression in various tumor types,
and therefore named a cancer-testis antigen (133). Members of
this family include MAGE, LAGE, XAGE, SSX, and other anti-
gens, all of which are intracellular molecules, with cytoplasmic
and/or nuclear expression. These antigens are controlled by epi-
genetic mechanisms and can be induced by hypomethylation or
deacetylation of promoter sequences (134). It is thought that as
tumors grow, some cells may be releasing antigens and initiat-
ing B-cell responses, and it is well established that detection of
antibodies against these tumor antigens is associated with tumor
antigen expression, even though there is no evidence that resulting
antibodies have a direct functional role against tumors (135). Not
much is known about what initiate immunogenicity, and whether
it happens at the tumor site from local TLS, or whether more
classic SLOs are responsible, after APCs carrying tumor extracts
migrate there. A positive correlation has been described between
size of LN B-cell areas and tumor-infiltrating B cells in head and
neck cancer patients treated with a mixture of cytokines (136),
suggesting that an interplay may be happening across SLOs and
local tumor environment. To address the question of the struc-
ture initiating humoral responses, one would need a dynamic
follow-up of antigen and uptake, and a better characterization
of TLS versus LN versus circulating B cells for their specificity and
chemokine receptor expression.
While B cells at the tumor site may recognize tumor antigens, it
is important to consider their role and potential clinical benefit in
a dynamic fashion as tumors evolve over time. Expression of most
cancer-testis antigens tends to increase with stage and grade of dis-
ease, as shown for melanoma, lung, myeloma, and ovarian tumors
among others, thereby highlighting more aggressive, poorly dif-
ferentiated tumors with usually worse outcome (137), but that
also become immunogenic as a result of new antigenicity. A study
has found that NY-ESO-1 protein expression in primary breast
carcinoma and metastases correlates with brisk plasmacytic B-cell
infiltration (138). It is likely however that by the time, the tumor
has reached a large enough size to generate B-cell response, the
resulting antibodies are insufficient to affect the disease. Recently,
tumor-infiltrating B cells were found increased in prostate cancer
tissue with high intra-tumoral density of B cells related to higher
stage and potential for recurrence or progression (139). In addi-
tion, B cells from ascites of ovarian cancer are able to produce
antibodies to known tumor antigens, though the presence of B
cells in ascites has been shown to increase with stage and to cor-
relate with poor prognosis, but to decrease by chemotherapeutic
treatment (140).
It is therefore important to view antibody responses as diverse
repertoires with polyfunctionality, not all of it associated with bet-
ter prognosis. Historically, circulating antibodies to tumor-specific
antigens were seen as a sign that cellular immunity was skewed in
favor of humoral rather than cellular responses, while CTLs were
preferred for their direct anti-tumor capacity (103, 141). Mutated
TP53 was one of the first tumor-associated antigens to be iden-
tified serologically (142), but circulating CTL responses against
TP53 appear to be rare (143). Despite abundant literature empha-
sizing the split between B cell and Th2-mediated immunity versus
cytotoxic CD8+ T cell and Th1 immunity, this dichotomy may
not be so clear for all tumor-associated antigens. In particular,
NY-ESO-1, one of the most spontaneously immunogenic antigens
from the cancer-testis family, is an example for which presence of
specific circulating antibodies typically implies concomitant pres-
ence of circulating effector-like CD4+ and CD8+ T cells, in an
integrated fashion (144, 145). Therefore, antibodies have been pro-
posed as a surrogate for T-cell immunity to NY-ESO-1. We showed
that patients seropositive for NY-ESO-1 have NY-ESO-1-specific
T cells accumulating at the tumor site in ovarian cancer patients,
though their activity was blunted by expression of co-inhibitory
molecules CTLA-4, PD-1, and LAG-3 (146). This may explain the
lack of anti-tumor effect, and therapeutic strategies to reverse such
responses will be discussed later. Nevertheless, these results sug-
gest that seropositivity could be a surrogate for the presence of
tumor-specific T cells infiltrating tumors.
Serum reactivities against tumor antigens have been described
in many cancer types, such as anti-NY-ESO-1 antibodies in
sarcoma (147) and primary breast cancer (148), anti-XAGE-
1b antibodies in NSCLC (3), anti-NY-ESO-1, anti-LAGE-1, and
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anti-P53 antibodies in ovarian cancer (18, 149). Very recently,
Ohue et al. showed that cancer patients with serum antibody-
reactivity against the tumor antigen XAGE1 had prolonged overall
survival as compared with seronegative patients (3). Similarly,
antibodies to MUC1 appeared to confer better survival in various
tumors, while p53 antibodies did the opposite (150). Circulating
antibody responses to NY-ESO-1, SOX2, Ubiquilin, and others
have been proposed as biomarkers for early detection of NSCLC
(151, 152), though few have been validated to date (153). Pres-
ence of circulating autoantibodies to tumor antigens has also
been well described in paraneoplastic syndrome, where speci-
ficities shared between tumors and the nervous system abruptly
lead to autoimmune pathology, albeit with some anti-tumor
benefit (154).
Some very recent studies have provided evidence that tumor-
specific humoral responses can be generated in situ, within TLS.
To characterize the specificity of local B cells at the tumor site,
we performed ex vivo cultures of NSCLC-infiltrating B cells and
showed that they were able to produce high levels of IgG and IgA
directed against tumor antigens of the cancer-testis antigen fam-
ily, such as LAGE-1, MAGE antigens, and NY-ESO-1, but also P53.
The reactivity we observed was polyclonal, as a same patient could
display reactivities against several different tumor antigens (39).
The presence of IgA at the tumor site is intriguing, as it differs
from the usual IgG detected in the periphery, and detailed reper-
toire analyses are still needed to distinguish potential differences
locally and systemically. More evidence of antigen-specific local
B cells was found in ductal breast carcinoma where infiltrating
B cells from TLS-like structures were microdissected and showed
polyclonality and high mutation rates, with some dominant clones
shared between various clusters of B cells suggesting affinity mat-
uration in situ and seeding from site to site (155). Finally, Maletzki
et al. observed in colorectal cancer that tumor-infiltrating B cells
produced IgG able to bind to the cell surface of several tumor cell
lines (156).
Once again though, mere presence of antibodies may not nec-
essarily be sufficient to predict outcome, as not all B-cell responses
are of equal quality. In lung cancer, a recent report indicated
increased circulating regulatory B cells [Bregs, reviewed in Ref.
(157)] but decreased Tregs compared to healthy donors, highlight-
ing a novel population of B cells to consider. It is likely that the
context of the original antigen stimulation (viral versus self, chron-
ically versus acutely inflamed) will drive the differentiation of the
B-cell repertoire, and this opens up strategies for manipulation
with immunotherapies.
TOWARD TLS- AND ANTIBODY-BASED THERAPEUTIC
STRATEGIES IN CANCER
It is assumed that the presence of TLS within tumors (except in
renal cell carcinoma) is always associated with prolonged survival
(27). Thus, a big challenge in the near future will be to develop
new therapeutic tools, or to determine therapeutic combinations,
able to favor the formation of such lymphoid structures in cancer
patients.
Several studies have already reported the development of TLS
as a consequence of antigen challenge during anti-tumor vaccina-
tion protocols. Lutz et al. for example observed the induction of
TLS in pancreatic ductal adenocarcinoma (PDAC) after vaccina-
tion with GM-CSF-secreting pancreatic tumor vaccine (GVAX),
a granulocyte-macrophage colony-stimulating factor (GM-CSF)-
secreting, allogeneic PDAC vaccine (158). While PDAC is classi-
cally considered as a non-immunogenic neoplasm, tumors from
patients vaccinated with GVAX presented organized and func-
tional TLS as soon as 2 weeks following GVAX treatment. These
TLS displayed all features of an ongoing immune response,
including GC B-cell proliferation, T-cell activation, and Th1
transcription factor T-bet expression, associated with the induc-
tion of IFNγ-expressing effector T-cell responses. The num-
ber of TLS detected within PDAC tumors tended to increase
when patients were treated with GVAX combined to the Treg-
depleting chemotherapy cyclophosphamide, in accordance with
studies showing that Tregs can suppress the development of TLS
(88, 98, 99, 159). More interestingly, a downregulation of genes
involved in the Treg pathway and a concomitant upregulation of
genes involved in the Th17 pathway was detected in TLS of patients
who survived longer and had enhanced immune responses. These
results are in accordance with studies claiming that, as opposed to
Tregs, Th17 cells and Th17 cytokines promote TLS development
(92, 93, 96, 97). Similarly, Maldonado et al. observed the forma-
tion of TLS in patients with high-grade cervical intraepithelial
neoplasias (CIN2/3) who received intramuscular therapeutic vac-
cination targeting HPV16 E6/E7 antigens (160). These TLS were
associated with HEVs, immune cell activation and Th1 polar-
ization signatures, and TCR clonality. In both studies, it seems
that vaccination-induced antigen-specific T cells generated sys-
temically were able to massively infiltrate the tumor microenvi-
ronment, and to initiate a local inflammatory reaction, further
favoring the recruitment of immune cells and TLS neogenesis.
Besides vaccination protocols, which aim to increase humoral
and cellular immune responses against particular tumor antigens,
several studies demonstrated that some chemotherapeutic drugs
have the capacity to enhance tumor immunogenicity and recogni-
tion by the immune system. Kroemer and Zitvogel groups notably
have extensively documented how anthracyclines and oxaliplatin
are able to trigger an immunogenic form of tumor cell death, and
thus to promote anti-tumor immune responses, through three
molecular mechanisms (161): first, the translocation of calretic-
ulin on the tumor cell surface, which results in tumor engulfment
by DCs; and secondly, the release by dying tumor cells of HMGB1
protein and ATP, two danger signals that bind TLR4 and P2X7
on DCs, respectively, and increase their ability to present tumor
antigens and to activate anti-tumor CD8+ T-cell responses (162–
164). Similarly, some DNA demethylating agents showed capaci-
ties to increase tumor immunogenicity, by favoring the expression
of cancer-testis antigens in cancer cells (165). Ayyoub et al. for
example demonstrated that DNA demethylation induced by 5-
aza-2′-deoxycytidine (5-AZA-CdR) increased or induced mRNA
expression of several cancer-testis antigens in sarcoma cell lines,
including MAGE-A10, SSX, NY-ESO-1, and LAGE-1, resulting in
increased tumor cell recognition by CTLs (147). Considering the
potential role played by DCs and B cells in TLS induction and/or
maintenance, we can speculate that chemotherapeutic drugs favor-
ing DC and/or B-cell activation may also have a beneficial effect
on the development of TLS within the tumor.
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Other developed strategies aim to directly induce the formation
of TLS within tumor tissue, by targeting at the tumor site signals or
chemokines known as favoring immune cell recruitment and/or
lymphoid neogenesis. Schrama et al. used the property of LTα to
promote TLS development in a mouse model of melanoma (166).
They developed an anti-disialoganglioside GD2 specific antibody-
LTα fusion protein, and demonstrated that this fusion protein
was able to favor subcutaneous tumor and established pulmonary
metastasis eradication, and to prolong survival. Twenty-eight days
after treatment, they could observe the presence of T cells and B
cells organized in lymphoid-like patterns within tumors, charac-
terized by the presence of MHC class II+ cells resembling DCs,
the presence of CD62L+ cells in close contact with PNAd+ HEVs.
Lymphoid neogenesis in the treated mice was associated with anti-
tumor T-cell clonal expansion. Similarly, Liang et al. used the
properties of the lymphoid chemokine CCL21 to favor the recruit-
ment of immune cells at the tumor site (167). In a mouse model
of hepatocellular carcinoma, they showed that the transduction
of tumor cells with a recombinant adeno-associated virus (rAAV)
expressing CCL21, or intra-tumoral injections of rAAV-CCL21,
allowed extensive infiltration of the tumor site by CD11c+ DCs
and activated CD3+ CD69+ T cells. Finally, Irvine et al. discussed
the possibility of using tissue engineering, and matrix or scaffold-
based approaches in order to create an implantable microenviron-
ment that would support the recruitment of immune cell and/or
favor lymphoid neogenesis through, for instance, the slow release
of chemoattractants (168).
We can hypothesize that strategies aiming at increasing or
re-activating exhausted T-cell responses, by targeting immunoreg-
ulators such as CTLA-4 or PD-1, may also have bystander effects
on TLS development. Beyond immune checkpoint inhibitors,
next generation immunomodulators may also involve costim-
ulatory agonists that can target both T and B cells, including
4-1BB, CD27, HVEM, and CD40 (169). Cross-linking capacity
of B cells was shown to be important for the therapeutic effect of
immunomodulatory antibodies such as anti-CD40 (170). These
novel strategies will need to be studied in detail for their role on
local immune infiltration and organization, through the design of
presurgical, neoadjuvant clinical studies. Another immunomod-
ulatory approach, beside systemic administration of antibodies
targeting immune pathways, may be to proceed with intra-tumoral
injections of pathogen-associated molecular patterns (PAMPs) or
cytokines, to change the inflammatory environment of the tumor.
BTLA was described as an inhibitor of some B-cell functions that
is upregulated in the context of immunotherapies including CpG
administration, but could be actionable with blocking of its inter-
action with natural ligand HVEM (171). Intra-tumoral injection
of IL-12 was also shown to activate B cells and lead to the polariza-
tion of immunoglobulin secretion to Th1-associated IgG1, along
with IFNγ production by B cells (17).
The detection of a humoral anti-tumor immune response
initiated within TLS and its characterization open the way to
the development of new vaccine and antibody-based therapeutic
strategies. As discussed above, reactivity against tumor antigens
belonging to the cancer-testis antigen family is a feature shared
by several cancer types, making these antigens as potential targets
in future protocols of immunotherapy. Despite their intracellular
expression, vaccines or monoclonal antibodies directed against
some of these antigens have already been validated in preclini-
cal models. Noguchi et al. for example demonstrated in mice the
anti-tumor effect of an anti-NY-ESO-1 antibody when associated
with chemotherapy (172). In this study, they observed not only the
generation of an anti-NY-ESO-1 CD8+ T-cell immune response,
but also the differentiation of other antigen-specific CD8+ T cells,
thanks to antigen spreading and DC activation by anti-NY-ESO-1
immune complexes (173).
MAGE-A3 and NY-ESO-1 have entered into clinical trials for
various cancers, and belong to the top 10 of the cancer antigens
referenced in the “Prioritization of Cancer Antigens” project pro-
posed by the National Cancer Institute (NCI) (174–177). Several
studies have already reported the development of both humoral
and cellular specific immune responses in NY-ESO-1-vaccinated
cancer patients (144, 178). In one study, it was suggested that
patients with the highest humoral responses following vaccina-
tion with NY-ESO-1 protein and CpG were more likely to have
associated induction of CD8+ T cells (179).
Finally, as described above, NY-ESO-1 is known to elicit sponta-
neous immune responses though their clinical benefit is not clear,
since the effector T cells at the tumor site may be dysfunctional
due to immune checkpoint inhibition (146). We asked if some of
the success of CTLA-4 blockade could be attributed to a change in
immune responses against NY-ESO-1, since it is a frequent antigen
in melanoma. We found that patients with pre-existing sero-
logical immunity to NY-ESO-1, coupled with detectable CD8+
T cells in the periphery, were nearly twice as likely to experi-
ence clinical benefit to ipilimumab compared to patients without
NY-ESO-1 immunity (180). Circulating antibody titers, CD8+
T-cell repertoire, and polyfunctionality to NY-ESO-1 increased
after treatment, but it is still unknown how ipilimumab affected
local tumor B and T-cell responses. However, the clinical benefit
suggests that having the tools to recognize NY-ESO-1 at base-
line will make it more likely that immunomodulatory treatment
will work.
CONCLUDING REMARKS
Tertiary lymphoid structures in human tumors contribute to an
environment conducive to the generation of B-cell diversity, with
the help of T cells and DCs that leads to accumulation of tumor-
specific immune responses inside or in proximity to the tumor.
The presence of such lymphoid structures, including their B-cell
component, underlines a population of patients that have already
been primed to react against their tumors, albeit immunosurveil-
lance has failed by the time the tumor is clinically detectable likely
due to many counter-regulatory mechanisms. Nevertheless, TLS,
along with T cells, mature DCs, and B cells, often predict even-
tual outcome in various diseases such as NSCLC, which suggests
that having a primed tumor immune microenvironment, i.e., local
immunocompetence, prior to treatment may facilitate various
interventions and slow down progression. However, with progres-
sion also comes a series of counter-regulatory mechanisms that
hamper the orchestrated anti-tumor immune responses, including
the B-cell repertoire.
Many questions remain to be answered however, such as iden-
tifying whether immune responses are originally primed locally
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in TLS and become systemic, or conversely are generated in clas-
sic lymphoid organs and migrate to the disease site. Investigating
differences in antigen cross-presentation, in antigen specificity
locally and systemically, in quality and function between tumor
B cells, LN B cells, and circulating B cells should help bring some
answers.
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